KindredBio announces positive results from KIND-014 for the treatment of gastric ulcers in horses

Seeking Alpha

Published May 30, 2018 08:17AM ET

KindredBio announces positive results from KIND-014 for the treatment of gastric ulcers in horses

  • Kindred Biosciences (NASDAQ:KIN) announces positive results from its pilot field study of KIND-014 for the treatment of gastric ulcers in horses.
  • This study was a placebo-controlled, dose-ranging study that enrolled 53 horses (40 horses in three groups with different doses and schedules, 13 in the placebo group). The objective was to determine the effective dose of KIND-014.
  • At Week 3, the gastric ulcer resolution (gastric ulcer score=0) rates in all three KIND-014 groups were statistically higher than the placebo group (p-values < 0.05).
  • Now read: Rocket Pharmaceuticals (RCKT) Presents At 2018 UBS Global Healthcare Conference - Slideshow

Original article

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes